These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26568036)

  • 1. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
    Irving JA
    Br J Haematol; 2016 Mar; 172(5):655-66. PubMed ID: 26568036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsed childhood acute lymphoblastic leukaemia.
    Bhojwani D; Pui CH
    Lancet Oncol; 2013 May; 14(6):e205-17. PubMed ID: 23639321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
    Locatelli F; Moretta F; Rutella S
    Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure.
    Beesley AH; Cummings AJ; Freitas JR; Hoffmann K; Firth MJ; Ford J; de Klerk NH; Kees UR
    Br J Haematol; 2005 Nov; 131(4):447-56. PubMed ID: 16281934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.
    Lee-Sherick AB; Linger RM; Gore L; Keating AK; Graham DK
    Br J Haematol; 2010 Nov; 151(4):295-311. PubMed ID: 20813012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Tasian SK; Hunger SP
    Br J Haematol; 2017 Mar; 176(6):867-882. PubMed ID: 27984637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia.
    Yan J; Jiang N; Huang G; Tay JL; Lin B; Bi C; Koh GS; Li Z; Tan J; Chung TH; Lu Y; Ariffin H; Kham SK; Yeoh AE; Chng WJ
    Br J Haematol; 2013 Oct; 163(1):93-103. PubMed ID: 23888996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.
    Han BW; Feng DD; Li ZG; Luo XQ; Zhang H; Li XJ; Zhang XJ; Zheng LL; Zeng CW; Lin KY; Zhang P; Xu L; Chen YQ
    Hum Mol Genet; 2011 Dec; 20(24):4903-15. PubMed ID: 21926415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia.
    Bhadri VA; Trahair TN; Lock RB
    J Paediatr Child Health; 2012 Aug; 48(8):634-40. PubMed ID: 22050419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
    Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
    Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
    Mullighan CG
    Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
    Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
    Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
    Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
    Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.
    Estrov Z; Ouspenskaia MV; Felix EA; McClain KL; Lee MS; Harris D; Pinkel DP; Zipf TF
    Leukemia; 1994 Jan; 8(1):46-52. PubMed ID: 8289497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance P--a potent risk factor in childhood lymphoblastic leukaemia.
    Nowicki M; Miśkowiak B
    Leukemia; 2003 Jun; 17(6):1096-9. PubMed ID: 12764374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
    Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
    Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
    Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
    Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.